Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.3M
Filings
8
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Dietary Supplement Innovation Act
2026 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Client expense: $180,000 · Firm income: —
Matched citations: HR.10336
Oral Health Products Inclusion Act
2026 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.1219-To amend the Internal Revenue Code of 1986 to include over-the-counter oral healthcare products as qualified medical expenses which can be purchased with HSA and FSA funds.
Client expense: $180,000 · Firm income: —
Matched citations: H.R.1219
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
2026 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Client expense: $180,000 · Firm income: —
Matched citations: H.R.9774
Oral Health Products Inclusion Act
2026 · second_quarter · Firm: CHATTEM, INC D/B/A OPELLA
Issues related to the regulatory pathway for dietary supplements; issues related to the regulatory pathway for non-prescription drugs; H.R.1219, Oral Health Products Inclusion Act.
Client expense: $200,000 · Firm income: —
Matched citations: H.R.1219
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2025 · fourth_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Client expense: $160,000 · Firm income: —
Matched citations: H.R.5371
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
2025 · fourth_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Client expense: $160,000 · Firm income: —
Matched citations: S.2529
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Client expense: $160,000 · Firm income: —
Matched citations: S.3122
Over-the-Counter Monograph Drug User Fee Amendments
2025 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
Client expense: $160,000 · Firm income: —
Matched citations: H.R.4273
Over-the-Counter Monograph Drug User Fee Amendments
2025 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
Client expense: $160,000 · Firm income: —
Matched citations: S.2292
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
2025 · third_quarter · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
Client expense: $160,000 · Firm income: —
Matched citations: S.2529
Source: Senate LDA